EKO International Corp – Summary of NeuroVascClinical Inc.’s (NVCI) Business
Burlington, Ontario
One of thegreatest challenge facing North American health care today is diabetes. It isestimated that there are 60 million diabetics in North American in 2012 andthat number is climbing rapidly. Approximately 65% of diabetics will developperipheral neuropathy, a painful and often irreversible condition affectingboth lower limbs. It begins as tingling and mild pain in the feet andeventually it becomes painless as the nerve function is compromised andsensation is lost. The loss of nerve function and decreased vascularity in the lowerlimb makes the patient susceptible to ulcers and wounds on the foot that willheal very slowly if at all. This opens up the risk for infection and greatlyincreases the likelihood of amputation. The cost in human terms and infinancial terms to the health care system is staggering. It is estimated thereis an amputation every 30 seconds in North America.
NeuroVascClinical Inc. has brought a solution to the North American market place. Thepatented technology called FREMS is an FDA and Health Canada approved devicethat uses a patented electrical frequency and duty cycle to stimulate bloodvessel re-growth and tissue regeneration in tissue that has compromised nerveand blood vessel function. The patient is treated 10 times once daily for 40minutes and the effects on the tissue will last up to 18 month depending on theoverall health of the patient. Thus this treatment becomes part of themaintenance of the lower limb for the diabetic patient as they age and will bea key player in the prevention of painful neuropathy and the development ofdangerous wounds.
Each FREMS devicecan treat approx. 8-10 patients a day.
The sale of eachFREMS device will generate approx. $ 8,000 of gross profit for EKO
Consumablesupplies for each treatment will generate approx. $3.00 of gross profit forEKO
NeuroVascClinical will be partnering with leading doctors and clinics in North Americato provide this service locally. Training and patient education will beprovided centrally by NeuroVasc Clinical and treatment will be provided atclinics certified by NeuroVasc Clinical locally.
Each FREMS deviceis expected to generate between $1,000 and $1,500 gross income per day for theclinics which are recommended to operate 3-5 devices per clinic.
NeuroVasc Clinicalis committed to seeking out world class partners and helping them provide thisinvaluable service to the diabetic population to prevent unwanted illness andeven early mortality.
This press release contains forward-lookingstatements that reflect the Company's current expectation regarding futureevents. Actual events could differ materially and substantially from thoseprojected herein and depend on a number of factors. Certain statements in thisrelease, and other written or oral statements made by Eko International (“TheCompany”) are "forward-looking statements" within the meaning ofSection 27A of the Securities Act of 1933 and Section 21E of the SecuritiesExchange Act of 1934. You should not place undue reliance on forward-lookingstatements since they involve known and unknown risks, uncertainties and otherfactors, which are, in some cases, beyond the Company's control and whichcould, and likely will, materially affect actual results, levels of activity,performance or achievements. The Company assumes no obligation to publiclyupdate or revise these forward-looking statements for any reason, or to updatethe reasons actual results could differ materially from those anticipated inthese forward-looking statements, even if new information becomes available inthe future. Important factors that could cause actual results to differmaterially from the company's expectations include, but are not limited to,those factors that are disclosed under the heading "Risk Factors" andelsewhere in documents filed by the company from time to time with the UnitedStates Securities and Exchange Commission and other regulatory authorities.
Tocontact the company by e-mail, please use info@ekointernational.com